TWD 70.7
(-3.42%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 606.71 Million TWD | 22.65% |
2022 | 494.67 Million TWD | 20.21% |
2021 | 411.49 Million TWD | -2.95% |
2020 | 424.01 Million TWD | -0.31% |
2019 | 425.33 Million TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 150.41 Million TWD | -7.83% |
2024 Q1 | 163.17 Million TWD | 5.46% |
2023 Q4 | 154.73 Million TWD | 4.54% |
2023 FY | 606.71 Million TWD | 22.65% |
2023 Q3 | 148.01 Million TWD | -4.63% |
2023 Q1 | 148.74 Million TWD | 5.39% |
2023 Q2 | 155.2 Million TWD | 4.34% |
2022 FY | 494.67 Million TWD | 20.21% |
2022 Q4 | 141.13 Million TWD | 0.0% |
2021 FY | 411.49 Million TWD | -2.95% |
2020 FY | 424.01 Million TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Allied Biotech Corporation | 720.43 Million TWD | 15.785% |
GeneFerm Biotechnology Co., Ltd. | 793.77 Million TWD | 23.566% |
Easywell Biomedicals, Inc. | 271.62 Million TWD | -123.361% |
TTY Biopharm Company Limited | 5.5 Billion TWD | 88.98% |
Synmosa Biopharma Corporation | 5.14 Billion TWD | 88.197% |
Orient EuroPharma Co., Ltd. | 4.59 Billion TWD | 86.787% |
Center Laboratories, Inc. | 1.39 Billion TWD | 56.477% |
Tien Liang BioTech Co., Ltd. | 459.99 Million TWD | -31.896% |
Orient Pharma Co., Ltd. | 889.91 Million TWD | 31.823% |
InnoPharmax Inc. | 46.07 Million TWD | -1216.847% |
Excelsior Biopharma Inc. | 771.56 Million TWD | 21.366% |
DV Biomed Co., Ltd. | 1.53 Billion TWD | 60.561% |
Foresee Pharmaceuticals Co., Ltd. | 195.03 Million TWD | -211.073% |
Handa Pharmaceuticals, Inc. | 1.1 Billion TWD | 45.16% |
UniPharma Co., Ltd. | 103.22 Million TWD | -487.773% |
Anxo Pharmaceutical Co., Ltd. | 939.94 Million TWD | 35.452% |
Alar Pharmaceuticals Inc. | 469.27 Million TWD | -29.288% |
Winston Medical Supply Co., Ltd. | 709.07 Million TWD | 14.436% |
Mercury Biopharmaceutical Corporation | 1.03 Million TWD | -58632.914% |
Bioray Biotech Co., Ltd | 191.83 Million TWD | -216.275% |
TSH Biopharm Corporation Limited | 810.91 Million TWD | 25.182% |